13 September 2021 - The main objective of this study was to evaluate the potential role of efficacy data and other information available at the time of price and reimbursement decision-making process within the definition of oncology treatment costs in Italy.

A total of 37 oncology drugs related to 58 therapeutic indications were analysed. 

The multivariate model showed that the variation of progression-free survival is the only variable predictor statistically associated with treatment cost, but this effect was observed only when confidential net prices were used (P=0.026).

Read Value in Health article